First Patient Recruited to Cohort 2 of Accent Trial
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Quarterly Activities and Cashflow Reports - December 2022
- Letter to Shareholders End of Year Summary and 2023 Plans
- Appendix 4D and Financial Report Half Year ended 30 Sep 22
- Amplia Appoints Dr Christopher Burns CEO & Managing Director
- Quarterly Activities and Cashflow Reports - Sep 2022 Qtr
Later from Amplia Therapeutics
- Dose Escalation Approved in ACCENT Clinical Trial of AMP945
- First Patient Recruited to Cohort 3 of ACCENT Trial
- Quarterly Activities and Cashflow Reports - March 23 Qtr
- ACCENT Trial Recruitment Progress
- Amplia receives grant to collaborate with CSIRO
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics